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Mean (SD) £ coll (log10) per II ver
3 li 48 h 72 h
Albumin 3-6 (0-2) 4-5 (0-10) 4-8 (0-01)
PolyHbXl 3*5 (0-1) 4-5(0-06) 4-8 (0-05)
Table: Proliferation of E coli 018 K l in livers of CBA/J mice
intravenous dose of a modified haemoglobin solution. They 
strongly suggested that modified haemoglobin solutions 
should not be used as blood substitutes in view of the risk of 
fulminating sepsis. We have carried out a similar study with 
a completely different outcome. A polymerised hum an 
haemoglobin solution (polyH bX l, developed at the Central 
Laboratory of the Netherlands Red Cross Blood Transfusion 
Service) was tested in a mouse infection model (12 animals) 
at a single intravenous dose of 15 mL/kg. An equivalent dose 
of hum an albumin solution served as control (12 animals). 
8X10* E  coli 018 K l (gift from E Griffiths) was inoculated 
intravenously 1 h  after the test solution, and the num ber of 
viable organisms in several organs was measured (table). N o 
difference was found in bacterial numbers between 
polyH bX l-treated and control mice and all animals 
survived. T he sensitivity of a comparable infection model in 
response to various modifiers has been shown previously.3
T he discrepancy between our findings and those of 
Griffiths et al may be due to differences between the 
haemoglobin solutions in purity, or stability of tissue 
distribution, to the use of different mouse strains, or to the 
different sites of inoculation of E  coli. W e find it puzzling 
that such a small difference in experimental design should 
have such a striking impact on outcome. Further study is 
needed to find out whether an increase in susceptibility to 
bacterial infections is a real hazard of haemoglobin-based 
blood substitutes.
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Subcutaneous immunoglobulin replacement in 
patients with primary antibody deficiencies
Sir—G ardulf et al (Feb 11, p 365) report that subcutaneous 
immunoglobulin (IgG) administration is a safe and 
convenient method for substitution in hypogamma- 
globulinaemic patients. We agree that adequate serum IgG  
concentrations can be achieved in compliant patients.1’2 We 
have found, however, that in many patients compliance with 
home treatment decreases (as shown by serum IgG  
concentrations <3 g/L), mainly because of pronounced and 
recurrent soreness at the site of infusion. This side-effect 
seems to be associated with certain batches of the 16% 
immunoglobulin preparations, possibly related to 
prekallikrein activator,3 and is not patient dependent. We 
have gradually switched to intravenous administration, and 
since 1990 this has been the m ethod used in m ost of our 
patients. Patients seem to prefer intravenous substitution to 
the subcutaneous method. To decrease costs and
inconvenience, we aim at adm inistration at hom e or at the 
surgery of the general practitioner. O f the  31 adult patients 
(12 women, 19 men, m ean age 42, range 18-79 years) with 
hypogammaglobulinaemia at our outpatient clinic, 29 
receive IgG substitution intravenously, 7 of them  receive 
infusions at hom e (mainly given by a partner), and 11 at the 
general practitioner's surgery. 1 patient uses IgG 
subcutaneously and 1 intramuscularly. T h e  patients report 
occasional mild systemic reactions (fever, chills, headache), 
b u t no severe reactions have been noted.
T he  yearly costs o f the im m unoglobulin preparations, 
based on an average o f 18 g per 4 weeks, are about 
US $5380 for subcutaneous treatm ent (syringe driver not 
included) compared with $9530 for intravenous treatm ent— 
a smaller difference than  in the Scandinavian study.
The indications for subcutaneous treatm ent in our setting 
for adults are limited to side-effects on intravenous therapy 
and poor venous access. In  children, die subcutaneous route 
is often preferred.
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increased urinary dipeptidyl peptidase IV 
activity in extrahepatic biliary atresia
Sir—Extrahepatic biliary atresia (EHBA) occurs in 1 in
10 000 to 1 in 20 000 live births. Survival of patients with 
EHBA increased substantially after die description of 
portoenterostomy by Kasai et al.' Successful re­
establishment of bile flow and long-term  survival after a 
Kasai operation depends on the age at the time of surgery.2'4 
Patients who cannot be treated with a Kasai procedure or 
who redevelop symptoms of hepatic failure due to the long­
term  consequences of recurring cholestasis are treated with 
liver transplantation, an operation not available in some 
countries. In Japan, a program m e has been developed to 
inform parents of patients to routinely watch for signs of 
cholestasis (white stool) and immediately seek help. It was 
hoped that this strategy would lead to earlier diagnosis of 
EHBA and to timely Kasai operations. However, recent 
evaluation of the program m e did no t show im provem ent in 
the age of patients at the time o f Kasai surgery,5 strongly 
indicating that a specific and easy-to-perform test is 
necessary for early diagnosis of EHBA.
W e tested the proteolytic enzyme, dipeptidyl peptidase IV 
(DPPIV), also known as C D 26, in the urine of control and 
EHBA patients. D PPIV  is present on the brush border of 
the bile canaliculi, renal tubules, and  gut epithelium and on 
the surface of some haem opoietic and T-lineage cells. U rine 
samples were collected from  35 healthy individuals at 2 -8  
weeks of age and from 4 EH B A  patients (6-8  weeks), U rine 
samples of 2 EHBA patients were analysed at different time 
points before Kasai surgery. All patients were jaundiced at 
the time of D PPIV  m easurem ents. EH BA  was diagnosed by
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